The China Food and Drug Administration (CFDA) has approved Ascletis' Category 1 new drug, Ganovo (Danoprevir or ASC08), for the treatment of viral hepatitis C.
Original Article: Ascletis' Ganovo gets CFDA approval for treatment of viral hepatitis C